The partnership brings together J&J’s antibodies and a university’s AAVs in a bid to open up a new frontier in the fight against the disease.

Pfizer dumped the drug after failing to find signs of efficacy in a phase 1 brain cancer trial, but iTeos thinks it has a future.

Next year will be a busy time for the European Medicines Agency as it looks to complete its move to Amsterdam.

While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.

At the end of the year, we all like to navel gaze, and editors are no different. It's a good time to reflect on what we write about, the importance of…

Will this year’s resurgence be sustained in 2018 in the face of a more uncertain environment?

Breakout Labs has backed over 30 companies since it handed out the first batch of grants in 2012.

The agreement gives Roche a potential source of small molecule agonists of an undisclosed G-protein coupled receptor.

Genentech is handing over an upfront fee and committing to milestones to apply DiCE’s small molecule platform to targets of interest.